Aralez Bio has unlocked a vast toolbox of noncanonical amino acids, enhancing Nimble’s platform and allowing us to tune peptides in ways that were not previously feasible… The icing on the cake is that the enzymatic process is significantly greener than ‘traditional’ amino acid synthesis.

Aralez provides an important service in production of protected non-canonical amino acids.  Their use of enzymatic chemistry to produce these amino acids is game changing and drives the industry to greener chemistry concepts.

We see a lot of headaches when R&D scientists expect the CMO to source or validate non-existent raw materials—or magically cut costs. They don’t realize that making a few milligrams in the lab isn’t enough for drug manufacturing. This needs to be addressed early in development, and [Aralez] could really help.

We spent thousands and waited 6–8 weeks for a CRO to build a single block, with no guaranteed success. Small molecule CRO timelines are so long that in-house work would be faster — but that’s not our expertise. I’d rather work with Aralez to truly shorten the product timeline. For R&D, timing is everything.

I’d rather do business in America with a one-step synthesis than a six- or seven-step process that needs to be outsourced to China. They promise five to seven weeks, but it often takes months — one product we ordered in February still isn’t here. Getting these amino acids faster will be a huge help.